Advertisement

Topics

Amgen’s Vectibix Receives Expanded Approval for Use in Wild-Type RAS Metastatic Colorectal Cancer

09:56 EDT 30 Jun 2017 | Speciality Pharma Journal

THOUSAND OAKS, Calif., June 29, 2017 /PRNewswire/ — Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) for Vectibix® (panitumumab) for patients with wild-type RAS (defined as wild-type in both KRAS and NRAS as determined by an FDA-approved test for this use) metastatic colorectal …

Original Article: Amgen’s Vectibix Receives Expanded Approval for Use in Wild-Type RAS Metastatic Colorectal Cancer

NEXT ARTICLE

More From BioPortfolio on "Amgen’s Vectibix Receives Expanded Approval for Use in Wild-Type RAS Metastatic Colorectal Cancer"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

Drug Approvals
In order to become availible to pateints, drugs need to undergo a number of phases of clinical trials to test their efficacy and safty and to then be authorised by the drug approval organistion in each respective country. This is the FDA in the USA and N...